drugset
drugset / Trial / NCT02187783

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

NCT02187783 ↗

Phase 2 Completed 106 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this signal seeking study was to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.

Timeline

Start
2014-08-25
Primary completion
2018-01-17
Completion
2018-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribociclib Small molecule 600 mg Oral

Indications

No indication recorded.